Comparison
Berberine vs Citicoline
Side-by-side of Berberine and Citicoline. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Side-by-side
| Attribute | Berberine | Citicoline |
|---|---|---|
| Category | natural | supplement |
| Also known as | berberine HCl, berberine hydrochloride | CDP-choline, cytidine 5'-diphosphocholine, Cognizin |
| Half-life (hr) ↗ | 3 | 56 |
| Typical dose (mg) ↗ | 1500 | 500 |
| Dosing frequency | 3x daily with meals | 1 to 2 times daily |
| Routes | oral | oral, intravenous |
| Onset (hr) | 2 | 1 |
| Peak (hr) | 3 | 2 |
| Molecular weight | 336.36 | 488.32 |
| Molecular formula | C20H18NO4+ | C14H26N4O11P2 |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | OTC supplement (US); Rx in most of the world |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Insufficient data for routine use |
| CAS | 2086-83-1 | 987-78-0 |
| PubChem CID | 2353 | 13804 |
| Wikidata | Q411435 | Q411470 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Which Should You Take?
Berberine and Citicoline score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
Edge case: Berberine is contraindicated in pregnancy; Citicoline is the safer pick if that applies.
Default choice: either is defensible. Berberine edges out on goal breadth + legal accessibility; Citicoline is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and Citicoline?
Berberine and Citicoline differ in category (natural vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or Citicoline?
Berberine half-life is 3 hours; Citicoline half-life is 56 hours.
Can you stack Berberine with Citicoline?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper